Latest Kaiser Health News Stories
Sen. Kyrsten Sinema has received almost $100,000 from drug companies in the current election cycle, a KHN analysis shows, one of the largest cash hauls in Congress. And it’s only her first term.
A Kaiser Health News database tracks campaign donations from drugmakers over the past 10 years.
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Thousands of researchers worldwide are looking for a treatment that will go beyond what remdesivir can do for COVID patients.
KHN’s Julie Rovner joins a panel of journalists on “1A” to talk about promising results in a study of the drug remdesivir and other developments in the battle against the coronavirus.
The Supreme Court this week, in an 8-1 decision, ruled that insurers are due the roughly $12 billion that Congress several years ago tried to cut off in payments under the Affordable Care Act’s “risk corridors” provision. And while the COVID-19 pandemic continues to rage in many places around the country, states are starting to reopen their economies at the urging of President Donald Trump and over objections of public health officials. Caitlin Owens of Axios and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Carmen Heredia Rodriguez, who wrote the latest KHN-NPR “Bill of the Month” installment about COVID testing that should have been free but was not.
Many Americans order drugs from Canada and other countries because they are cheaper, but U.S. authorities appear to be cracking down on the practice.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
The politics of COVID-19 are pretty polarized, but health experts across the ideological spectrum agree: The U.S. will need more robust testing before it’s safe to relax social-distancing requirements. Meanwhile, President Donald Trump, Congress and the nation’s governors continue to spar over who should be responsible for what. Kimberly Leonard of Business Insider, Tami Luhby of CNN and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
The proposal being weighed by federal officials would allow employers and insurers to decide that drug companies’ assistance doesn’t count toward their members’ deductible or out-of-pocket maximum spending limits. If plans opted for that approach, only payments made by patients themselves would be included in the calculation toward reaching those limits.
Josie and George Taylor of Everett, Washington, are two of the first people in the U.S. to recover from novel coronavirus infections after joining a clinical trial for the antiviral drug remdesivir.
Six states — Idaho, Louisiana, Nevada, North Carolina, Ohio and Texas — have taken steps to limit inappropriate prescriptions for the medicine and preserve supplies for patients who take it for lupus and rheumatoid arthritis.
Three senators on a revived subcommittee received more than $100,000 each from drugmakers.
Fifteen percent of hospital pharmacists who prepare injectable drugs are going without the protective masks they typically use or are using substitutes for masks.
After Kaiser Health News’ questions, the association tells the aspirin maker to take down display bins at Walmart pharmacies that gave a false impression that the over-the-counter drug is recommended for everyone to prevent heart attacks.
Since gaining control of the House, Senate and governor’s office, Colorado Democrats are pushing an aggressive health care agenda. With measures to create a public insurance option, welcome drug importation, lower drug prices, curtail surprise billing and cap insulin copays, the state is becoming a likely model for health policies at the federal level.
Health care experts thought the battle was won against heart disease, measles, smoking, STDs and other life-threatening conditions and behaviors. Better think again.
The California Democratic members of Congress who flipped seven Republican seats two years ago made health care a major campaign issue, criticizing their opponents for voting to repeal the Affordable Care Act. As the Democrats defend their seats in this year’s elections, they are coming back to health care — but the issues are different.
Candidates’ tough health policy talk strayed far from hope for unity.